{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:54:17Z","timestamp":1790193257385,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007856","name":"Baylor College of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR190043"],"award-info":[{"award-number":["RR190043"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.canlet.2026.218591","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:15:00Z","timestamp":1779466500000},"page":"218591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nanoplasmid PSMA DNA vaccine primes antitumor immunity and enhances response to PD-1 blockade against prostate cancer"],"prefix":"10.1016","volume":"655","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9984-5668","authenticated-orcid":false,"given":"Perry Ayn Mayson A.","family":"Maza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2424-7267","authenticated-orcid":false,"given":"Dana","family":"Cyril-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4291-6223","authenticated-orcid":false,"given":"Praveen","family":"Neeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-1714","authenticated-orcid":false,"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218591_bib1","first-page":"485","article-title":"Prostate cancer statistics, 2025","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218591_bib2","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218591_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218591_bib4","first-page":"227","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218591_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13143556","article-title":"Evolving castration resistance and prostate specific membrane antigen expression: implications for patient management","volume":"13","author":"Kessel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218591_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J. Surg."},{"key":"10.1016\/j.canlet.2026.218591_bib7","series-title":"Direct Gene Transfer into Mouse Muscle in vivo","author":"Wolff","year":"1990"},{"key":"10.1016\/j.canlet.2026.218591_bib8","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1073\/pnas.90.24.11478","article-title":"DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations","volume":"90","author":"Fynan","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218591_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/vaccines1030225","article-title":"Vector design for improved DNA vaccine efficacy, safety and production","volume":"1","author":"Williams","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2026.218591_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.omtn.2023.04.003","article-title":"Improving cell and gene therapy safety and performance using next-generation Nanoplasmid vectors","volume":"32","author":"Williams","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2026.218591_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioelechem.2021.107981","article-title":"Reduction of plasmid vector backbone length enhances reporter gene expression","volume":"144","author":"Boye","year":"2022","journal-title":"Bioelectrochemistry"},{"key":"10.1016\/j.canlet.2026.218591_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioelechem.2021.107892","article-title":"Bioelectrochemistry Cardioporation enhances myocardial gene expression in rat heart","volume":"142","author":"Boye","year":"2021","journal-title":"Bioelectrochemistry"},{"key":"10.1016\/j.canlet.2026.218591_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-0556-1-2","article-title":"DNA vaccines: improving expression of antigens","volume":"1","author":"Garmory","year":"2003","journal-title":"Genet. Vaccines Ther."},{"key":"10.1016\/j.canlet.2026.218591_bib14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/pros.23770","article-title":"PSMA expression in the Hi-Myc model; extended utility of a representative model of prostate adenocarcinoma for biological insight and as a drug discovery tool","volume":"79","author":"Simons","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218591_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajur.2018.11.005","article-title":"Metastatic prostate cancer remains incurable, why?","volume":"6","author":"Dong","year":"2019","journal-title":"Asian J. Urol."},{"key":"10.1016\/j.canlet.2026.218591_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw261","article-title":"Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218591_bib17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrurol.2015.33","article-title":"Immunotherapy: Sipuleucel-T induces humoral antigen spread in patients with mCRPC","volume":"12","author":"Sidaway","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.canlet.2026.218591_bib18","first-page":"1","volume":"109","author":"Gulley","year":"2017"},{"key":"10.1016\/j.canlet.2026.218591_bib19","doi-asserted-by":"crossref","first-page":"52810","DOI":"10.18632\/oncotarget.10547","article-title":"Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer","volume":"7","author":"Graff","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218591_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/pros.23311","article-title":"Novel monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) as research and Theranostic tools","volume":"77","author":"Nov\u00e1kov\u00e1","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218591_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218591_bib22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","article-title":"Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation","volume":"39","author":"Duraiswamy","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218591_bib23","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1096\/fj.201800636R","article-title":"Lack of acute xenogeneic graft-versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression","volume":"33","author":"Brehm","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2026.218591_bib24","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.canlet.2026.218591_bib25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218591_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: Intermediate-\/High-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer Consensus conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218591_bib27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2026.218591_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218591_bib29","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"166","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2026.218591_bib30","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1002\/cam4.2375","article-title":"Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer","volume":"8","author":"Tucker","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218591_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2024.2315655","article-title":"Immunotherapy resistance in solid tumors: mechanisms and potential solutions","volume":"25","author":"Lefler","year":"2024","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2026.218591_bib32","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218591_bib33","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","article-title":"Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","volume":"19","author":"Tagawa","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218591_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/proc\/9766669","article-title":"Cellular immunotherapy for prostate cancer: lessons learned from 15 years of sipuleucel\u2010T","volume":"2025","author":"Shore","year":"2025","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.canlet.2026.218591_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/mt.2012.244","article-title":"Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level","volume":"21","author":"Gracey Maniar","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218591_bib36","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.gt.3302231","article-title":"Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo","volume":"11","author":"Chen","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2026.218591_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4161\/hv.7.0.14574","article-title":"Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses","volume":"7","author":"Ferraro","year":"2011","journal-title":"Hum. Vaccines"},{"key":"10.1016\/j.canlet.2026.218591_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24132-6","article-title":"Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells","volume":"12","author":"Burbach","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218591_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib40","doi-asserted-by":"crossref","first-page":"64447","DOI":"10.18632\/oncotarget.10901","article-title":"Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer","volume":"7","author":"Wadosky","year":"2016","journal-title":"Oncotarget."},{"key":"10.1016\/j.canlet.2026.218591_bib41","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218591_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106870","article-title":"The Th1\/Th2 paradigm: a misrepresentation of helper T cell plasticity","volume":"268","author":"Rogozynski","year":"2024","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.canlet.2026.218591_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature14347","article-title":"The evolutionary history of lethal metastatic prostate cancer","volume":"520","author":"Gundem","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218591_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26840-5","article-title":"Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression","volume":"12","author":"Bolis","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218591_bib47","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer.The Cancer Genome Atlas Research Network","volume":"163","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218591_bib48","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","article-title":"Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique","volume":"50","author":"Mhawech-Fauceglia","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2026.218591_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fruro.2022.912558","article-title":"PSMA as a target for advanced prostate cancer: a systematic review","volume":"2","author":"Belbina","year":"2022","journal-title":"Front. Urol."},{"key":"10.1016\/j.canlet.2026.218591_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040806","article-title":"Tumor heterogeneity: a great barrier in the age of cancer immunotherapy","volume":"13","author":"El-Sayes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218591_bib51","series-title":"Article Engineered T Cells Stimulate Dendritic Cell Recruitment and Antigen Spreading for Potent Anti- Tumor Immunity ll Engineered T Cells Stimulate Dendritic Cell Recruitment and Antigen Spreading for Potent Anti-tumor Immunity","author":"Xiao","year":"2025"},{"key":"10.1016\/j.canlet.2026.218591_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in prostate cancer: from a \u201cCold\u201d Tumor to a \u201cHot\u201d prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218591_bib53","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218591_bib54","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218591_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-011145","article-title":"PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy","volume":"13","author":"Moseman","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218591_bib56","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.molcel.2025.09.008","article-title":"The RIG-I-like receptor family of immune proteins","volume":"85","author":"van Huizen","year":"2025","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2026.218591_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41590-018-0292-y","article-title":"Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47\u2212mediated \u2018don\u2019t-eat-me\u2019 signal","volume":"20","author":"Liu","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-08180-0","article-title":"The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy","volume":"16","author":"Xie","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218591_bib61","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218591_bib62","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful Anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218591_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-024-00979-w","article-title":"DNA vaccines against GPRC5D synergize with PD-1 blockade to treat multiple myeloma","volume":"9","author":"Neeli","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.canlet.2026.218591_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01597","article-title":"PD-1\/PD-L1 blockade: have we found the key to unleash the antitumor immune response?","volume":"8","author":"Xu-Monette","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218591_bib68","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"T follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218591_bib69","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3892\/ol.2015.3522","article-title":"Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCID\u03b3 mouse (Mus musculus) anterior prostate","volume":"10","author":"Cifuentes","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2026.218591_bib70","volume":"vols. 1\u201324","author":"Guerin","year":"2020"},{"key":"10.1016\/j.canlet.2026.218591_bib71","doi-asserted-by":"crossref","first-page":"25586","DOI":"10.18632\/oncotarget.25387","article-title":"Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer","volume":"9","author":"McNeel","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218591_bib72","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000020281","article-title":"Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I\/II clinical trial","volume":"38","author":"Mincheff","year":"2000","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2026.218591_bib73","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","article-title":"DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time","volume":"61","author":"Chudley","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218591_bib74","doi-asserted-by":"crossref","first-page":"xi5","DOI":"10.1093\/annonc\/mdx710.007","article-title":"INO-5150 (PSA and PSMA) +\/- INO-9012 (IL-12) immunotherapy in biochemically relapsed prostate cancer","volume":"28","author":"Csiki","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218591_bib75","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1158\/1078-0432.CCR-24-3693","article-title":"Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer","volume":"31","author":"Galsky","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218591_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217421","article-title":"Vaccines targeting p53 mutants elicit anti-tumor immunity","volume":"611","author":"Chai","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218591_bib77","article-title":"Pre-clinical orthotopic murine model of human prostate cancer","volume":"611","author":"Shahryari","year":"2016","journal-title":"J Vis Exp."},{"key":"10.1016\/j.canlet.2026.218591_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.650841","article-title":"Inotodiol from Inonotus obliquus Chaga mushroom induces atypical maturation in dendritic cells","volume":"12","author":"Maza","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600354X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352600354X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:35:43Z","timestamp":1783164943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352600354X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":78,"alternative-id":["S030438352600354X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218591","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoplasmid PSMA DNA vaccine primes antitumor immunity and enhances response to PD-1 blockade against prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218591"}}